AXSMAxsome Therapeutics, Inc.
$168.44+45% 1Y
$168.44
$116.0152 weeks$255.17
AXSM in its own filings
AXSM's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
298
Events found in the filings · across 670 filings · the record starts in 2015
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 10, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 22, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- Restatement admitted (non-reliance)historical
- 2016-07-12
- Change in certifying accountanthistorical
- 2023-06-26
- SEC comment-letter activity7 occurrences
- 2016-12-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026On August 10, 2026, the Company updated its corporate presentation and posted such corporate presentation to the Company’s website.Earnings release · Form 8-K
- Jul 15, 2026On July 15, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy.Other event · Form 8-K
- Jun 3, 2026Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation.Other event · press release
- May 4, 2026On May 4, 2026, the Company updated its corporate presentation and posted such corporate presentation to the Company’s website.Earnings release · Form 8-K
- Apr 30, 2026On April 30, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved AUVELITY ® for the treatment of agitation associated with dementia due to Alzheimer’s disease.Other event · Form 8-K
- Apr 1, 2026On April 1, 2026, Axsome Therapeutics, Inc. issued a press release entitled “Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and other Neuropsychiatric Conditions.” For purposes of this.Other event · Form 8-K
- Feb 23, 2026Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Feb 17, 2026On February 17, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI ® (solriamfetol)Other event · Form 8-K
- Jan 12, 2026As reported above, on January 12, 2026, the Company issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” For purposes of this.Earnings release · Form 8-K
- Dec 31, 2025On December 31, 2025, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing the U.S. Food and Drug Administration’s acceptance and grant of Priority Review for its supplemental New Drug Application for the treatment of Alzheimer’s Disease Agitation.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…